Skip to content
10-Q

Quarterly Report

RIGEL PHARMACEUTICALS INC RIGL

0001034842-26-000032

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 18.5M sh
Shares Diluted Q1 2026 · Mar 31, 2026 19.69M sh
Shares Diluted Q1 2026 · Mar 31, 2025 18.17M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $3.74M
Stock Repurchased Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 $2.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$893K
Long Term Debt Q1 2026 · Mar 31, 2026 $45M
Short Term Investments Q1 2026 · Mar 31, 2026 $122.27M
Short Term Investments Q1 2026 · Dec 31, 2025 $114.38M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $24.41M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $40.58M
Stockholders Equity Q1 2026 · Mar 31, 2026 $399.9M
Stockholders Equity Q1 2026 · Dec 31, 2025 $391.48M
Stockholders Equity Q1 2026 · Mar 31, 2025 $18.57M
Stockholders Equity Q1 2026 · Dec 31, 2024 $3.29M
Current Liabilities Q1 2026 · Mar 31, 2026 $89.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $99.24M
Total Liabilities Q1 2026 · Mar 31, 2026 $104.71M
Total Liabilities Q1 2026 · Dec 31, 2025 $122.11M
Current Assets Q1 2026 · Mar 31, 2026 $234.03M
Current Assets Q1 2026 · Dec 31, 2025 $240.17M
Total Assets Q1 2026 · Mar 31, 2026 $504.61M
Total Assets Q1 2026 · Dec 31, 2025 $513.59M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.44
Eps Diluted Q1 2026 · Mar 31, 2025 $0.63
Eps Basic Q1 2026 · Mar 31, 2026 $0.47
Eps Basic Q1 2026 · Mar 31, 2025 $0.64
Sga Expense Q1 2026 · Mar 31, 2026 $30.65M
Sga Expense Q1 2026 · Mar 31, 2025 $27.72M
Rd Expense Q1 2026 · Mar 31, 2026 $11.68M
Rd Expense Q1 2026 · Mar 31, 2025 $8.44M
Net Income Q1 2026 · Mar 31, 2026 $8.65M
Net Income Q1 2026 · Mar 31, 2025 $11.45M
Operating Income Q1 2026 · Mar 31, 2026 $11.89M
Operating Income Q1 2026 · Mar 31, 2025 $12.77M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $4.61M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $4.41M
Revenue Q1 2026 · Mar 31, 2026 $58.82M
Revenue Q1 2026 · Mar 31, 2025 $53.33M